Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02422940 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.
A Phase 3 study, sponsored by Acorda Therapeutics.
- Terminated
- Registry status
- Phase 3
- Development phase
- 294
- Enrollment target
NCT02422940: Clinical Trial Phase 3 study, sponsored by Acorda Therapeutics.
NCT02422940 is a Phase 3 study that was terminated before completion, run by Acorda Therapeutics. The registered enrollment target is 294 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02422940, a Phase 3 study, was terminated before completion, sponsored by Acorda Therapeutics.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 294 participants
- Enrollment target
Study Summary
This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
Primary Outcome
This extension study was designed to evaluate long-term safety, tolerability, and efficacy of dalfampridine-ER (extended release) in adult subjects with chronic post-ischemic stroke walking deficits. Subjects who had completed the placebo-controlled DALF-PS-1016 core study were eligible to enroll regardless of whether they had received active drug or placebo in the core study.
Interventions
- DRUG dalfampridine-ER 7.5 mg
- DRUG dalfampridine-ER 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 294 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Why NCT02422940 stopped before completion
NCT02422940 is an interventional study that assigns participants to a tested intervention. The registered 294 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which dalfampridine-ER 7.5 mg is the first listed.
NCT02422940 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02422940 about?
NCT02422940 is a clinical study titled "Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine.". This is an extension study to evaluate the long-term safety, tolerability, and efficacy of two dose strengths of dalfampridine-ER.
What is the current status of trial NCT02422940?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 294 participants. The study started on 2015-04. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02422940?
The interventions under investigation include: dalfampridine-ER 7.5 mg (DRUG), dalfampridine-ER 10 mg (DRUG).
Who is sponsoring clinical trial NCT02422940?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02422940's enrollment target sits among peer trials
294 1166th of 2000 higher than 835 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia